Hôpital de la Croix-Rousse

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  "Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis

  NCT07889726· University Hospital, Toulouse· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

  NCT07545512· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial

  NCT07081763· Phase 2· ANRS Maladies Infectieuses Emergentes· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· Phase 3· Unicancer· Source

• Not yet recruiting

  Development of a Predictive Score for the Risk of Infection in the Immediate Post-liver-transplant Period

  NCT07647978· Hospices Civils de Lyon· Source

• Not yet recruiting

  Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG

  2025-523610-83-00· Phase 4· Institut Gustave Roussy· Source

• Recruiting

  Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

  NCT07566195· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Residual Sleepiness and Accident Risk in Treated Obstructive Sleep Apnea

  NCT07545421· Hospices Civils de Lyon· Source

• Recruiting

  Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

  NCT07585890· University Medical Center Groningen· Source

• Recruiting

  PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)

  NCT07393074· Hospices Civils de Lyon· Source

• Not yet recruiting

  Food-related Quality of Life in Patients With Cancer

  NCT07437326· Hospices Civils de Lyon· Source

• Not yet recruiting

  ActiTENS Mini (Transcutaneous Electrical Stimulation) in Women With Chronic Pain From Pelvic Endometriosis

  NCT07317037· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

  NCT06254248· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

  NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  HOPE Against Cancer Recurrence in HCC

  NCT06717919· Phase 4· Philipp Dutkowski· Source

• Recruiting

  Impact of Nutritional Management on the Frailty of Patients Waiting for Liver Transplantation (Via the LFI Tool)

  NCT06911619· Hospices Civils de Lyon· Source

• Recruiting

  Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI

  NCT06501482· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

  NCT06943469· Société des Produits Nestlé (SPN)· Source

• Recruiting

  Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

  NCT06932263· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  NCT06878261· Phase 3· AstraZeneca· Source

• Recruiting

  Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial

  NCT06522256· ANRS, Emerging Infectious Diseases· Source

• Recruiting

  Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

  NCT06487273· Physio-Assist· Source

• Recruiting

  A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

  NCT06767683· Phase 2/3· Alkermes, Inc.· Source

• Recruiting

  A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

  NCT06659549· Phase 2· Galimedix Therapeutics Inc· Source

• Recruiting

  Microbial and Environmental Factors Associated With Polyps Development in Familial Adenomatous Polyposis (MicrobEnvironment in FAP)

  NCT06614738· Hospices Civils de Lyon· Source

• Recruiting

  Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy

  NCT06562283· Centre Hospitalier Universitaire de Saint Etienne· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Recruiting

  Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions

  NCT06457945· Hospices Civils de Lyon· Source

• Recruiting

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  2024-512895-36-00· Phase 3· Akero Therapeutics Inc.· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus

  NCT06356740· Phase 2· Hospices Civils de Lyon· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· ARCAGY/ GINECO GROUP· Source

• Recruiting

  Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care

  NCT06331676· Hospices Civils de Lyon· Source

• Recruiting

  National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis

  NCT06356831· Centre Hospitalier Intercommunal Creteil· Source

• Recruiting

  Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study.

  NCT06119516· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  2023-505141-48-00· Phase 3· Akero Therapeutics Inc.· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Recruiting

  EGEA4 THE 30 YEAR FOLLOW UP OF THE EGEA STUDY

  NCT06334705· Institut National de la Santé Et de la Recherche Médicale, France· Source

• Recruiting

  Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

  NCT05710679· Centre Jean Perrin· Source

Showing 50 of 89.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)7 recruiting
• Liver cirrhosis7 recruiting
• Liver and biliary tract cancer6 recruiting
• Lung cancer5 recruiting
• Colorectal cancer4 recruiting
• COPD4 recruiting
• Endometriosis4 recruiting
• Hepatitis B4 recruiting
• Macular degeneration4 recruiting
• Bronchiectasis3 recruiting
• Ovarian cancer3 recruiting
• HIV2 recruiting
• Kidney cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Narcolepsy2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis C1 recruiting
• High blood pressure1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Obesity1 recruiting
• Obstructive sleep apnoea1 recruiting
• Sarcoma1 recruiting
• Sjögren's disease1 recruiting
• Spinal muscular atrophy1 recruiting

Closed trials

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· AstraZeneca AB· Source

• Active, not recruiting

  ​Clinical trial of patritumab deruxtecan in people with gastrointestinal cancers​

  2024-512442-41-00· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Psychological, Sociological and Professional Factors Associated With Maintenance of Wakefulness Test

  NCT06586138· Hospices Civils de Lyon· Source

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

  NCT06465186· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  HEMAGO Monitoring and Impact on the Occurrence of Complications During Pregnancy in Sickle Cell Patients

  NCT06620887· Hospices Civils de Lyon· Source

• Completed

  Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

  NCT06020014· Phase 2· AstraZeneca· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Terminated

  Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

  NCT05900050· Phase 2· Genfit· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases

  NCT05546606· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Completed

  Assessment of Tobacco Smoking and Alcohol Drinking and Treatment Outcomes Among Patients With Lung or Head and Neck Cancer

  NCT05523583· Hospices Civils de Lyon· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

  NCT05158387· Phase 3· AstraZeneca· Source

• Completed

  A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

  NCT05123599· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Completed

  Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

  NCT04903626· Phase 3· AbbVie· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

  NCT04746924· Phase 3· Beigene Ltd.· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops (NIH) Fetalis by Massively Parallel Sequencing

  NCT04308603· Hospices Civils de Lyon· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source

• Completed

  A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

  NCT04567615· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Bayer· Source

• Completed

  A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

  NCT04439539· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

  NCT04527107· Phase 2· Oxurion· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Galectin Therapeutics Inc.· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Regeneron Pharmaceuticals· Source

• Completed

  Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

  NCT04233879· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

  NCT04223778· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Endometriosis and Pain

  NCT03993197· Hospices Civils de Lyon· Source

• Completed

  A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

  NCT04039607· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

  NCT04042558· Phase 2· Centre Francois Baclesse· Source

• Completed

  FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

  NCT03723967· Phase 2· Centre Leon Berard· Source

• Completed

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Boston Scientific Corporation· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Gyroscope Therapeutics Limited· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

• Completed

  Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

  NCT03547908· Phase 3· Gilead Sciences· Source

• Completed

  A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation

  2023-508726-10-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

  NCT03364153· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Macular degeneration16 works · 10 trials
• Sarcoidosis11 works · 0 trials